BNP Paribas Starts Astrazeneca at Outperform Rating, $75 Price Target
AstraZeneca (AZN) Receives a Buy From UBS
Goldman Sachs Maintains AstraZeneca(AZN.US) With Buy Rating, Raises Target Price to $196.51
Goldman Sachs Sticks to Its Buy Rating for AstraZeneca (AZN)
Barclays Sticks to Its Buy Rating for AstraZeneca (AZN)
AstraZeneca (AZN) Gets a Hold From Deutsche Bank
Analysts Offer Insights on Healthcare Companies: United Therapeutics (UTHR), Roche Holding AG (OtherRHHVF) and AstraZeneca (AZN)
Bernstein Sticks to Their Buy Rating for AstraZeneca (AZN)
AstraZeneca's Promising Pipeline and Strategic Positioning in Lung Cancer Treatment Earns Buy Rating
AstraZeneca (AZN) Receives a Buy From UBS
AstraZeneca (AZN) Receives a Buy From J.P. Morgan
Goldman Sachs Maintains AstraZeneca(AZN.US) With Buy Rating, Raises Target Price to $98
AstraZeneca (AZN) Gets a Hold From Deutsche Bank
AstraZeneca (AZN) Gets a Buy From Goldman Sachs
J.P. Morgan Sticks to Their Buy Rating for AstraZeneca (AZN)
J.P. Morgan Remains a Buy on AstraZeneca (AZN)
TD Cowen Maintains AstraZeneca(AZN.US) With Buy Rating, Announces Target Price $95
AstraZeneca (AZN) Gets a Buy From Barclays
Goldman Sachs Sticks to Its Buy Rating for AstraZeneca (AZN)
AstraZeneca (AZN) Gets a Buy From UBS